Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 549-564

  Tjan Heijnen, Vivianne C G ^a   Postmus, Pieter E ^b   Wagener, D J Theo ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Dose intensification; Hematopoietic growth factors; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; STEM CELLS;

EID: 0030881773     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00002     Document Type: Review

References (125)

1. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46: 516-25.
2. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15: 278-99.
3. Maurer LH, Tulloh M, Weiss RB, et al. A randomized combined modality trial in small cell carcinoma of the lung. Comparison of combination chemotherapy radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic brain irradiation. Cancer 1980; 45: 30-9.
4. Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 1986; 17: 157-60.
5. Byrne MJ, van Hazel G, Trotter J, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer 1989; 60: 413-8.
6. Medical Research Council Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59: 584-90.
7. Gìaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11: 1230-40.
8. Ettinger DS, Finkelstein DM, Abeloff MD, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8: 230-40.
9. Spiro SG, Souhami RL. Duration of chemotherapy in small cell lung cancer. Thorax 1990; 45: 1 2.
10. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59: 578 83.
11. Medical Research Council Lung Cancer Working Party A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Br J Cancer 1993; 68: 1150-6.
12. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 3643-53.
13. Livingston RB, Mira JG, Chen TT, McGavran M, Costanzi JJ, Samson M. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1984; 2: 585 90.
14. Havemann K, Wolf M, Holle R, et al. Alternating versus sequential chemotherapy in small cell lung cancer. Cancer 1987; 59: 1072-82.
15. Viallet J, Ihde DC. Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited. J Clin Oncol 1989; 7: 985-7.
16. Skipper HE, Schabel FM. Tumor stem cell heterogenity: implications with respect to classification of cancer by chemotherapeutic effect. Cancer Treat Rep 1984; 68: 43-61.
17. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-8.
18. Souhamì RL, Ruiz de Elvira MC. Chemotherapy dose intensity in small cell lung cancer. Lung Cancer 1994; 10 (Suppl 1): S175-85.
19. Broder LE, Cohen MH, Selawry OS. Treatment of bronchogenic carcinoma. II. Small cell. Cancer Treat Rev 1977; 4: 219-60.
20. Souhami RL, Harper PG, Linch D, et al. High-dose cyclophosphamide with autologous bone marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 1983; 10: 205-7.
21. Souhami RL, Finn G, Gregory WM, et al. High-dose cyclophosphamide in small cell carcinoma of the lung. J Clin Oncol 1985; 3: 958-63.
22. Pedersen AG, Hansen HH. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev 1983; 10: 245-64.
23. Luikart SD, Propert KJ, Modeas CR, Green MR, Perry MC. High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep 1987; 71: 533-4.
24. Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986; 70: 583-7.
25. Wolff SN, Johnson DH, Hande KR, Hainsworth JD, Greco FA. High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67: 957-8.
26. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40.
27. Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987; 20: 248-52.
28. Klasa RJ, Murray N, Coldman AJ. Dose-intensity metaanalysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499-508.
29. Gurney H, Dodwell D, Thatcher N, Tattersall MH. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice - part 2. Ann Oncol 1993; 4: 103-15.
30. Abeloff MD, Ettinger DS, Order SE, et al. Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat Rep 1981; 65: 639-46.
31. Fahra P, Spitzer G, Valdivieso M, et al. High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small-cell lung carcinoma. Cancer 1983; 52: 1351-5.
32. Thatcher N, James RD, Steward WP, et al. Three months' treatment with cyclophosphamide, VP16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer 1985; 56: 1332-6.
33. Thatcher N, Stout R, Smith DB, et al. Three months' treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer 1985; 52: 327-32.
34. Johnson DH, DeLeo MJ, Hande KR, Wolff SN, Hainsworth JD, Greco FA. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small cell lung cancer. J Clin Oncol 1987; 5: 703-9.
35. Cohen MH, Creaven PJ, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349-54.
36. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54-64.
37. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5: 1731-8.
38. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848-52.
39. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 1994; 12: 2022-34.
40. Vathaire de F, Arriagada R, Thé de H, et al. Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung carcinoma. Lung Cancer 1993; 8: 301-8.
41. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.
42. Stewart P, Buckner CD, Thomas ED, et al. Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67: 1055-9.
43. Smith LE, Evans BD, Harland SJ, et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-4.
44. Cunningham D, Banham SW, Hutcheon AH, et al. High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung. Cancer Chemother Pharmacol 1985; 15: 303-6.
45. Sculier JP, Klastersky J, Stryckmans P, et al. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol 1985; 3: 184-91.
46. Spitzer G, Fahra P, Valdivieso M, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4: 4-13.
47. Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4: 1443-54.
48. Marangolo M, Rosti G, Amadori D, et al. High-dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study. Bone Marrow Transplant 1989; 4: 405-8.
49. Sculier JP, Klastersky J. High-dose chemotherapy of small-cell lung cancer with and without bone marrow transplantation. In: Hamsen HH, ed. Basic and clinical concepts of lung cancer. Boston: 1989; XIII: 259-74.
50. Goodman GE, Crowley J, Livingston RB, Rivkin SE, Albain K, McCulloch JH. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group Study. J Clin Oncol 1991; 9: 453 7.
51. Elias AD, Ayash L, Frei III E, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 1993; 85: 559 66.
52. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous hone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864-73.
53. Taylor CW, Crowley J, Williamson SK, et al. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol 1990; 8: 1811-7.
54. Miles DW, Earl HM, Souhami RL, et al. Intensive-weekly chemotherapy for good-prognosis patients with small cell lung cancer. J Clin Oncol 1991; 9: 280-5.
55. Murray N, Shah A, Osoba D, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991; 9: 1632 8.
56. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11: 1858-65.
57. Souhami RL, Rudd R, Ruiz de Elvira M-C, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign Trial. J Clin Oncol 1994; 12: 1806-13.
58. Metcalf D. The molecular biology and cloning of the granulocyte-macrophage colony-stimulating factors. Blood 1986; 67: 257-74.
59. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: biology and clinical applications. N Engl J Med 1989; 321: 1449-59.
60. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64-9.
61. Fleischmann J, Golde DW, Weisbart RH, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986; 68: 708-11.
62. Lopez AF, Nicola NA, Burgess AW, et al. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. J Immunol 1983; 131: 2983 8.
63. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/ II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56: 809-13.
64. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; i: 667-72.
65. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82: 1454-61.
66. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. Effect of recombinant human granulocyte colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. New Engl J Med 1987; 317: 593-8.
67. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593-8.
68. Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic response in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989; 7: 159 67.
69. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48: 731 60.
70. Avalos BR, Gasson JC, Hedvat C, et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990; 75: 851-7.
71. Baldwin GC, Gasson JC, Kaufman SE, et al. Non-hematopoietic tumor cells express functional GM-CSF receptors. Blood 1989; 73: 1033-7.
72. Gurney H, Anderson H, Radford J, et al. Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Cancer 1992; 28: 105-12.
73. Wolf M, Haveman K. Experience with GM-CSF in the treatment of solid tumors. Infection 1992; 20 (suppl 2): S111-5.
74. Bishop JF, Morstyn G, Stuart-Harris R, et al. Dose and schedule of granulocyte macrophage colony stimulating factor (GM-CSF), carboplatin and etoposide in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991; 10: 820 (abstr).
75. Crawford J, Kreisman H, Garewal H, et al. A pharmacodynamic investigation of recombinant human granulocyte colony-stimulating factor (r-methuG-CSF) schedule variation in patients with small-cell lung cancer (SCLC) given CAE chemotherapy. Proc Am Soc Clin Oncol 1992; 11: 1005 (abstr).
76. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
77. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
78. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70.
79. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-24.
80. Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K. Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol 1994; 21: 43-7.
81. Miles DW, Fogarty O, Ash CM, et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12: 77-82.
82. Hamm J, Schiller JH, Cuffie C, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994; 12: 2667-76.
83. Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-41.
84. Schmidberger H, Hess CF, Hoffmann W, Reuss-Borst MA, Bamberg M. Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy. Eur J Cancer 1993; 14: 1927-31.
85. Lyman GH, Lyman CG, Sanderson RA, Williams SD, Loehrer PJ, Einhorn LH. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 488-93.
86. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 1245-50.
87. Biesma B, Vries EGE de, Willemse PHB, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1990; 26: 932-6.
88. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 492-501.
89. Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803-8.
90. Vellenga E, Uyl-de Groot CA, Wit R de, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14: 619-27.
91. De Jongh CA, Wade JC, Finley RS, et al. Trimethoprim/sulfamethoxazole versus placebo: A double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol 1983; 1: 302-7.
92. Lüppo K, Nikkanen V, Heinonen E. Carboplatin and etoposide in advanced lung cancer: a phase I study. Cancer Chemother Pharmacol 1990; 27: 229-33.
93. Tueni E, Sculier JP, Klastersky J. Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. Eur J Cancer Clin Oncol 1988; 24: 963-7.
94. Katakami N, Takada M, Negoro S, et al. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. Cancer 1996; 77: 63-70.
95. Luikart SDW, Herzan D, Modeas C, et al. Ability of daily or twice daily granulocyte-macrophage colony-stimulating factor (GM-CSF) to support dose escalation of etoposide (VP-16) and carboplatin (CBDCA) in extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991; 10: 825 (abstr).
96. Eguchi K, Etou H, Miyachi S, et al. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer 1994; 30A: 188-94.
97. Mitchell EP, Luikart SD, Van Echo DA, et al. Etoposide (VP-16) and cisplatin (DDP) in untreated extensive small cell lung cancer (SCLC): a dose-escalation study Proc Am Soc Clin Oncol 1988; 7: 206 (abstr).
98. Shepherd FA, Goss PE, Rusthoven J, Eisenhauer EA. Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1992; 84: 59-60.
99. Paccagnella A, Favaretto A, Riccardi A, et al. Granulocyte-macrophage colony stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Cancer 1993; 72: 697-706.
100. Ardizzoni A, Sertoli MR, Corcione A, et al. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study. Eur J Cancer 1990; 26: 937-41.
101. Ardizzoni A, Venturini M, Crinò L, et al. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 1993; 29A: 687-92.
102. Thatcher N, Clark PI, Smith DB. et al. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; Filgrastim) in the treatment of small cell lung cancer (SCLC). Clin Oncol 1995; 7: 293-9.
103. Thatcher N, Anderson H, Bleehen NM, et al. on behalf of the Medical Research Council Lung Cancer Working Party. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor to increase the planned dose intensity of doxorubicin cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer (SCLC). Eur J Cancer 1995; 31A: 152-6.
104. O'Byrne KJ, Philip PA, Stuart NSA, et al. Increased dose-intensity of epirubicin and ifosfamide in small cell lung cancer using r-metHuG-CSF. Br J Cancer 1994; 69 (suppl XXI): 44 (abstr).
105. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13: 652-9.
106. Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-81.
107. Socinski MA, Cannista SA, Elias A, et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194-8.
108. Socinsky MA, Cannistra SA, Sullivan R, et al. Human granulocyte-macrophage colony-stimulating factor induces the expression of the C11b surface adhesion molecule on granulocytes in vivo. Blood 1988; 72: 691-7.
109. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous hone marrow transplantation. Lancet 1989; ii: 891-5.
110. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
111. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
112. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-5.
113. Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-44.
114. Shimizu E, Yamamoto A, Takahashi Y, et al. Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood. Br J Cancer 1993; 67: 798-800.
115. Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L. Use of high-dose etoposide/ifosfamide/ carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Semin Oncol 1995; 22 (suppl 2): 3-8.
116. Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intenisve therapy. J Clin Oncol 1992; 10: 464 73.
117. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-56.
118. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamicle: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
119. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121-5.
120. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993; 45: 788-856.
121. Ozols RF. Cisplatin dose-intensity. Semin Oncol 1989; 16 (suppl 6): 22-30.
122. Gandara DR, Crowley J, Livingstone RB, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11: 873-8.
123. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Oncology Group protocol. J Clin Oncol 1991; 9: 1163-72.
124. Ozols RF, Thigpen JT, Dauplat J, et al. Advanced ovarian cancer. Dose intensity. Ann Oncol 1993; 4 (suppl 4): 49-56.
125. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8.